Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

387.75 +8.42 (+2.22%)

Streaming Delayed Price Updated: 1:53 PM EST, Feb 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9

...

64 65 Next >

The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026

Today 10:18 EST

As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the...

Via Finterra

Topics Economy Intellectual Property

Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial

February 23, 2026

The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a...

Via MarketMinute

Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head

February 23, 2026

Shares of Eli Lilly (NYSE: LLY) climbed 3.5% on February 23, 2026, as the pharmaceutical giant tightened its grip on the multi-billion-dollar obesity market. The rally was fueled by disappointing...

Via MarketMinute

Amgen CEO Teases 2026 As ‘Springboard Year’ After 14 Blockbusters And 18 Record Products ↗

February 04, 2026

Via Stocktwits

Amgen Inc (NASDAQ:AMGN) Beats Q4 2025 Estimates and Provides Strong 2026 Revenue Guidance ↗

February 03, 2026

Via Chartmill

Novo Nordisk Shares Plunge 13% as Next-Gen Weight Loss Drug CagriSema Fails to Topple Eli Lilly in Landmark Trial

February 23, 2026

COPENHAGEN — Shares of the Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) plummeted more than 13% in premarket trading on Monday, February 23, 2026, following the release of highly anticipated...

Via MarketMinute

Topics Earnings

February 22, 2026

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can...

Via StockStory

1 Momentum Stock to Research Further and 2 We Avoid

February 18, 2026

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant...

Via StockStory

The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth

February 17, 2026

In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion...

Via MarketMinute

Topics Earnings Economy

Gilead Sciences and the 2026 Biotech Resurgence: A Leader in the Great Rotation

February 13, 2026

As of February 13, 2026, the financial markets are witnessing a historic "Great Rotation," where institutional capital is flowing out of overextended technology valuations and into the defensive,...

Via MarketMinute

Topics Artificial Intelligence ETFs Government

1 Large-Cap Stock Worth Your Attention and 2 We Avoid

February 12, 2026

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for...

Via StockStory

The 5 Most Interesting Analyst Questions From Amgen’s Q4 Earnings Call

February 10, 2026

Amgen’s fourth-quarter results reflected broad-based sales growth across its diverse portfolio, with management crediting strong volume gains in key products such as Repatha, Evenity, and Tezspire. CEO...

Via StockStory

Topics Earnings

The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts

February 05, 2026

In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a...

Via MarketMinute

Topics Earnings Economy

Trump Administration To Launch TrumpRx Platform For Discounted Drugs Later On Thursday: Reports ↗

February 05, 2026

The medications that will be offered via the platform include Novo Nordisk’s popular weight-loss drug Wegovy, Eli Lilly and Company's Zepbound, Amgen’s cholesterol drug Repatha, and Merck’s diabetes...

Via Stocktwits

Topics Economy Government World Trade

Healthcare Titans Propel Dow to Record Highs as GLP-1 Sales Spark Major Market Rotation

February 05, 2026

As the first week of February 2026 unfolds, a dramatic shift in investor sentiment has split the U.S. stock market. While technology and artificial intelligence stocks have faced a sharp pullback, the...

Via MarketMinute

Topics Artificial Intelligence Earnings Intellectual Property

These 2 Companies Could Soon Join the Weight Loss Market: Are They Buys? ↗

February 05, 2026

Wegovy might be getting more competition soon.

Via The Motley Fool

Topics Intellectual Property

The $1 Trillion Apothecary: A Deep-Dive Research Report on Eli Lilly (LLY)

February 05, 2026

As of February 5, 2026, Eli Lilly and Company (NYSE: LLY) stands as a paradigm-shifting titan in the global healthcare landscape. Having recently crossed the historic $1 trillion market capitalization...

Via Finterra

Topics Earnings Economy Intellectual Property

Why Is Amgen Stock Falling Premarket? ↗

February 05, 2026

Wall Street’s updated price targets on Amgen imply a wide range from about 16% downside to a 15% upside from the stock’s last close.

Via Stocktwits

Explore the top gainers and losers within the S&P500 index in today's session. ↗

February 04, 2026

Via Chartmill

Wednesday's session: top gainers and losers in the S&P500 index ↗

February 04, 2026

Via Chartmill

AMGN Q4 Deep Dive: Product Portfolio Expansion and Pipeline Progress Drive Outlook

February 04, 2026

Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 8.6% year on year to $9.87 billion. The company’s full-year revenue guidance of $37.7 billion at...

Via StockStory

Amgen (AMGN) Q4 2025 Earnings Call Transcript ↗

February 03, 2026

Amgen (AMGN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Amgen (NASDAQ:AMGN) Reports Upbeat Q4 CY2025

February 03, 2026

Biotech company Amgen (NASDAQ:AMGN) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 8.6% year on year to $9.87 billion. The company’s full-year revenue guidance of...

Via StockStory

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative...

Via MarketMinute

Topics ETFs Government Initial Public Offering

Amgen (AMGN) Reports Q4: Everything You Need To Know Ahead Of Earnings

February 01, 2026

Via StockStory

Topics Artificial Intelligence

Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy. ↗

January 28, 2026

Amgen may not have an approved GLP-1 treatment just yet, but that could change in the future.

Via The Motley Fool

The $100 Billion Milestone: Johnson & Johnson Pivots from 'Steady' 2025 to Growth-Focused 2026

January 27, 2026

NEW BRUNSWICK, N.J. — Johnson & Johnson (NYSE: JNJ) has officially closed the chapter on a year many analysts described as "transitional," reporting full-year 2025 earnings that met expectations while...

Via MarketMinute

Topics Earnings Economy Government

The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed

January 26, 2026

The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market...

Via Finterra

Topics Economy Initial Public Offering

Q3 Rundown: Amgen (NASDAQ:AMGN) Vs Other Therapeutics Stocks

January 25, 2026

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Amgen (NASDAQ:AMGN) and its peers.

Via StockStory

Topics Artificial Intelligence

Johnson & Johnson 2026 Outlook: Chasing the $100 Billion Milestone Amidst Legal and Patent Hurdles

January 23, 2026

Following a resilient performance throughout 2025, healthcare giant Johnson & Johnson (NYSE: JNJ) has officially set its sights on a historic milestone for 2026. In its latest earnings report released...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

< Previous 1 2 3 4 5 6 7 8 9

...

64 65 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.